Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras-related protein Rap-2c (RAP2C)
- Target
- RAP2C
- Molecular classification
- Small GTPase, Ras oncogene family, Ras superfamily of small GTPases, Enzyme (GTP-binding protein)
01
Overview
Ras-related protein Rap-2c (RAP2C) is a member of the Ras oncogene family of small GTPases, which act as molecular switches in signal transduction pathways. RAP2C, along with RAP2A and RAP2B, regulates a variety of cellular processes including cytoskeletal organization, cell adhesion, migration, and invasion, critical for both physiological and pathological conditions. Recent evidence shows that RAP2C promotes migration and invasion of cancer cells, acting via upregulation of MMP2 activity and stimulation of the PI3K/Akt signaling pathway, but does not impact cell proliferation or apoptosis. Its role in facilitating cancer cell motility and metastatic potential makes RAP2C a candidate therapeutic target, though no approved drugs selectively target it yet.
- Other names
- RAP2CDKFZp313B211Small GTPase RAP2CRas-related protein Rap-2c
02
Mechanism of action
Drugs or inhibitors targeting RAP2C would likely modulate its GTPase activity, thereby affecting cell migration/invasion signaling pathways such as increased MMP2 production and PI3K/Akt-mediated cell motility
03
Biological functions
Signal transductionRegulation of cell migrationRegulation of cell invasionCytoskeletal organizationCell adhesionRegulation of matrix metalloproteinase activityRegulation of Akt phosphorylation
04
Disease associations
Cancer (tumor progression, metastatic potential, especially in osteosarcoma)Other (potential role in cell motility and invasiveness in various cancers)
05
Safety considerations
No specific safety concerns have been documented for RAP2C-targeting agents, but as the pathway is central to cell migration and invasion, unintended effects on normal cell motility and tissue repair could be anticipated
06
Interacting drugs
No clinically approved drugs directly targeting RAP2C have been documented; experimental targeting has been proposed but is not yet established
07
Biomarkers
MMP2 (matrix metalloproteinase-2, levels increased with RAP2C activity)TIMP2 (tissue inhibitor of metalloproteinases 2, levels decrease with RAP2C activity)Phosphorylated Akt (p-Akt)
Beyond the preview
Go deeper on Ras-related protein Rap-2c (RAP2C).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ras-related protein Rap-2c (RAP2C).